Aragon Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on the treatment of hormone-resistant cancers, with an intital focuse on prostate and breast cancer, closed a $42M Series C financing. Participants include Aisling Capital, OrbiMed, Column Group and Topspin Partners.

Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.